Clinical Neuropsychology: Open Access
Open Access

Neurological disorders; Deep brain stimulation; Gene Therapy; Neurostimulation; Neural plasticity

Introduction

Neurological disorders are a broad category of conditions that affect the brain, spinal cord, and nerves throughout the body. These disorders can cause a wide range of symptoms, including cognitive impairment, movement disorders, sensory disturbances, and changes in behavior or mood. Over the years, significant advancements have been made in understanding the underlying mechanisms of neurological disorders and developing innovative treatment approaches [1, 2]. This article explores some of the recent breakthroughs in the field of neurological disorders (Table 1).

Table 1: Different categories of neurological disorder and their corresponding methods of treatment.

Precision medicine: tailoring treatments to individual patients

One of the most promising developments in neurological disorder research is the application of precision medicine. Precision medicine aims to customize treatment strategies based on an individual's specific genetic makeup, environmental factors, and lifestyle. This approach allows for more targeted therapies and can potentially enhance treatment outcomes for patients with neurological disorders such as Alzheimer's disease, Parkinson's disease, and epilepsy [3].

Deep brain stimulation (dbs): revolutionizing treatment for movement disorders

Deep Brain Stimulation (DBS) has emerged as a transformative treatment option for individuals with movement disorders, including Parkinson's disease and essential tremor. DBS involves implanting electrodes into specific regions of the brain and delivering electrical impulses to modulate abnormal neural activity. Recent advancements in DBS technology, such as the use of directional leads and closed-loop systems, have improved treatment precision and reduced side effects, providing patients with significant relief from their symptoms [4].

Gene therapy: a promising frontier

Gene therapy holds tremendous potential for treating various neurological disorders caused by genetic abnormalities. By delivering healthy genes into the affected cells, researchers have shown promising results in treating disorders like spinal muscular atrophy (SMA) and certain types of inherited neuropathies. Recent advancements in gene editing techniques, such as CRISPR-Cas9, have accelerated progress in this field, bringing us closer to effective gene-based therapies for neurological disorders [5].

Neurostimulation and neurofeedback: harnessing the power of brain plasticity

Neurostimulation and neurofeedback techniques aim to modulate brain activity and promote neural plasticity to improve symptoms associated with neurological disorders. Transcranial Magnetic Stimulation (TMS) and transcranial Direct Current Stimulation (tDCS) are non-invasive techniques that have shown promise in various conditions, including depression, migraines, and stroke recovery. Neurofeedback, which involves training individuals to self-regulate their brain activity, has also demonstrated potential in managing conditions like Attention Deficit Hyperactivity Disorder (ADHD) and Post-Traumatic Stress Disorder (PTSD) [6].

Methodology

Conducting a comprehensive review of existing literature is crucial to understand the current state of knowledge regarding neurological disorders. This involves analyzing relevant research papers, clinical studies, and reviews to identify gaps, trends, and emerging concepts. Fundamental research is essential for unraveling the underlying mechanisms of neurological disorders. This includes studying cellular and molecular processes, genetic factors, neural circuits, and the role of neurotransmitters in normal and diseased states. Techniques like cell culture, animal models, and advanced imaging technologies (e.g., MRI, PET, fMRI) are commonly employed [7].

Clinical research plays a vital role in understanding the clinical manifestations, diagnosis, and progression of neurological disorders. Observational studies, cohort studies, case-control studies, and clinical trials are conducted to gather data on patient populations, disease characteristics, treatment outcomes, and potential biomarkers. Ethical considerations and informed consent are crucial components of clinical studies. Advanced neuroimaging techniques are employed to visualize and analyze the structure and function of the brain. Magnetic resonance imaging (MRI), positron emission tomography (PET), Single-Photon Emission Computed Tomography (SPECT), and functional MRI (fMRI) allow researchers and clinicians to study brain abnormalities, identify biomarkers, and monitor treatment responses [8].

Investigating the genetic basis of neurological disorders provides insights into disease mechanisms and potential therapeutic targets. Genome-Wide Association Studies (GWAS), whole-exome sequencing, and whole-genome sequencing are employed to identify genetic variations and mutations associated with specific disorders. The field of precision medicine utilizes individual patient characteristics, including genetic profiles, lifestyle factors, and environmental influences, to tailor treatment strategies. This involves the integration of clinical data, genetic testing, and bioinformatics analysis to develop personalized treatment plans [9].

Translating research findings into clinical practice is crucial for advancements in neurological disorder treatment. This involves bridging the gap between basic science discoveries and their application in patient care. Preclinical models, biomarker development, and validation studies are conducted to facilitate the transition from bench to bedside. Advancements in medical technologies, such as Deep Brain Stimulation (DBS), neurostimulation, neurofeedback, and braincomputer interfaces, are explored to develop innovative treatment approaches for neurological disorders. These technologies often undergo rigorous testing and clinical trials to assess safety, efficacy, and long-term outcomes [10]. Collaboration among researchers, clinicians, pharmaceutical companies, and regulatory bodies is crucial for advancing the field of neurological disorders. Sharing data, expertise, and resources promotes a multidisciplinary approach and accelerates progress in understanding and treating these complex disorders.

Results

Advancements in neuroimaging techniques, such as MRI and PET, have facilitated more accurate and earlier diagnoses of neurological disorders. This allows for timely intervention and personalized treatment planning. Research efforts have led to the discovery of potential biomarkers associated with neurological disorders. These biomarkers can aid in early detection, disease monitoring, and predicting treatment responses. Precision medicine approaches have shown promise in tailoring treatments to individual patients based on their genetic profiles and other factors [11]. This personalized approach aims to optimize treatment effectiveness and minimize side effects. Deep Brain Stimulation (DBS) and other neurostimulation techniques have demonstrated significant improvements in symptom management for movement disorders, such as Parkinson's disease and essential tremor. Patients often experience reduced motor symptoms and improved quality of life.

Gene therapy has shown promising results in treating certain genetic neurological disorders, including Spinal Muscular Atrophy (SMA) and inherited neuropathies. By introducing healthy genes or modifying faulty genes, researchers have observed improvements in symptoms and disease progression. Neurorehabilitation techniques, including neurofeedback and brain-computer interfaces, have shown potential in promoting recovery and improving function in individuals with neurological disorders such as stroke, traumatic brain injury, and neurodevelopmental disorders [12]. Increased collaboration between researchers, clinicians, and industry stakeholders has fostered significant advancements in understanding the complex mechanisms of neurological disorders. These collaborative efforts have led to more comprehensive research studies and accelerated progress in treatment development.

Discussion

Unraveling disease mechanisms: Advancements in basic science research have deepened our understanding of the intricate mechanisms underlying neurological disorders. By studying cellular and molecular processes, researchers have identified key factors contributing to disease development and progression. This knowledge provides a foundation for the development of targeted therapies and interventions [13].

Precision medicine and personalized treatment: The emergence of precision medicine has ushered in an era of personalized treatment approaches. By considering an individual's genetic makeup, biomarkers, and clinical characteristics, healthcare professionals can tailor treatments to suit each patient's unique needs. This approach maximizes treatment efficacy, minimizes adverse effects, and enhances overall patient outcomes.

Neuroimaging technologies: Advanced neuroimaging techniques, such as functional MRI (fMRI), Diffusion Tensor Imaging (DTI), and Positron Emission Tomography (PET), have significantly contributed to the understanding and diagnosis of neurological disorders. These technologies allow clinicians and researchers to visualize and study brain structure, connectivity, and metabolic activity, aiding in early detection, accurate diagnosis, and monitoring of disease progression [14]. Genetic discoveries and gene therapy: The identification of genetic factors associated with neurological disorders has opened new avenues for targeted interventions. Advances in gene therapy, including gene editing techniques like CRISPR-Cas9, offer the potential to correct or modify disease-causing genetic mutations. This approach holds promise for treating previously incurable genetic neurological disorders. Therapeutic interventions: Innovative therapeutic interventions, such as Deep Brain Stimulation (DBS), neurostimulation, and neurofeedback, have transformed the treatment landscape for various neurological disorders. These approaches modulate neural activity, restore balance, and alleviate symptoms, significantly improving the quality of life for patients with conditions like Parkinson's disease, epilepsy, and chronic pain [15]. Multidisciplinary collaboration: Collaboration among researchers, clinicians, patients, and industry stakeholders is crucial in advancing the understanding and treatment of neurological disorders. By pooling resources, expertise, and data, collaborative efforts can accelerate progress, promote knowledge sharing, and enhance the translation of research findings into clinical practice.

While these advancements hold great promise, challenges remain. Neurological disorders are often complex and multifaceted, requiring continued research and innovative approaches. Additionally, ensuring access to these advancements, addressing healthcare disparities, and managing ethical considerations are important considerations for equitable implementation [16].

Advancements in understanding and treating neurological disorders have the potential to transform healthcare and improve the lives of individuals affected by these conditions. Through interdisciplinary research, personalized approaches, and innovative interventions, we can strive to unravel the complexities of these disorders and provide effective treatments that positively impact patients and their families. Continued efforts in research, collaboration, and implementation are key to further advancing our knowledge and capabilities in the field of neurological disorders [17].

Conclusion

Advancements in understanding the mechanisms of neurological disorders and developing innovative treatments have paved the way for improved patient care and management. From precision medicine to gene therapy and neurostimulation techniques, researchers and clinicians are working tirelessly to unravel the complexities of neurological disorders and find effective solutions. While challenges remain, these recent breakthroughs offer hope for individuals living with neurological disorders and hold the promise of a brighter future in neurological healthcare.

Acknowledgement

None

Conflict of Interest

Not declared.

1. Olsen LF, Issinger OG, Guerra B (2013) The Yin and Yang of redox regulation. Redox Rep 18: 245-252.

Google Scholar, Crossref, Indexed at

2. Pernas L, Scorrano L (2016) Mito-morphosis: mitochondrial fusion, fission, and cristae remodeling as key mediators of cellular function. Annu Rev Physiol 78: 505-531.

Google Scholar, Crossref, Indexed at

3. Alston CL, Rocha MC, Lax NZ, Turnbull DM, Taylor RW (2017) The genetics and pathology of mitochondrial disease. J Pathol 241: 236-250.

Google Scholar, Crossref, Indexed at

4. Ong SB, Kalkhoran SB, Hernandez-Resendiz S, Samangouei P, Ong SG, et al. (2017) Mitochondrial-shaping proteins in cardiac health and disease – the long and the short of it!. Cardiovasc Drugs Ther 31: 87-107.

Google Scholar, Crossref, Indexed at

5. Yu T, Robotham JL, Yoon Y (2006) Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci U S A 103: 2653-2658.

Google Scholar, Crossref, Indexed at

6. Jheng HF, Tsai PJ, Guo SM, Kuo LH, Chang CS, et al. (2012) Mitochondrial fission contributes to mitochondrial dysfunction and insulin resistance in skeletal muscle. Mol Cell Biol 32: 309-319.

Google Scholar, Crossref, Indexed at

7. Tailor D, Hahm ER, Kale RK, Singh SV, Singh RP (2014) Sodium butyrate induces DRP1-mediated mitochondrial fusion and apoptosis in human colorectal cancer cells. Mitochondrion 16: 55–64.

Google Scholar, Crossref, Indexed at

8. Kondrup J, Rasmussen HH, Hamberg O, Stanga Z, Group AHEW (2003) Nutritional risk screening (NRS 2002):  A new method based on an analysis of controlled clinical trials. Clin Nutr 22: 321–336.

Google Scholar, Crossref, Indexed at

9. Marcadenti A, Mendes LL, Rabito EI, Fink JDS, Silva FM (2018) Nutritional Risk in Emergency-2017:  A New Simplified Proposal for a Nutrition Screening Tool. J Parenter Enter Nutr 42: 1168–1176.

Google Scholar, Crossref, Indexed at

10. Arslan M, Soylu M, Kaner G, İnanç N, Başmısırlı E (2016) Evaluation of malnutrition detected with the Nutritional Risk Screening 2002 (NRS-2002) and the quality of life in hospitalized patients with chronic obstructive pulmonary disease. Hippokratia 20: 147–152.

Google Scholar, Indexed at

11. Chen R, Xing L, You C (2017) The use of nutritional risk screening 2002 to predict prognosis in hospitalized patients with chronic obstructive pulmonary disease with respiratory failure. Eur J Intern Med 43: e9–e10.

Google Scholar, Crossref, Indexed at

12. Chen R, Xing L, You C, Ou X (2018) Prediction of prognosis in chronic obstructive pulmonary disease patients with respiratory failure:  A comparison of three nutritional assessment methods. Eur J Intern Med 57: 70–75.

Google Scholar, Crossref, Indexed at

13. Ingadottir AR, Bjorgvinsdottir EB, Beck A, Baldwin C, Weekes C, et al. (2020) Effect of two different nutritional supplements on postprandial glucose response and energy- and protein intake in hospitalised patients with COPD:  A randomised cross-over study. Clin Nutr 39: 1085-1091.

Google Scholar, Crossref, Indexed at

14. Ogan N, Yıldırım F, Süzen B, Baha A, Akpınar EE (2020) Does Nutritional Risk Screening 2002 Correlate with the Dyspnea Status of Patients with GOLD Stage C-D Chronic Obstructive Pulmonary Disease?. Turkish Thorac J 21: 49–53.

Crossref

15. Maia I, Peleteiro B, Xará S, Amaral TF (2017) Undernutrition Risk and Undernutrition in Pulmonology Department Inpatients:  A Systematic Review and Meta-Analysis. J Am Coll Nutr 36: 137–147.

Google Scholar, Crossref, Indexed at

16. Law S, Kumar P, Woods S, Sriram KB (2016) Malnutrition screening in patients admitted to hospital with an exacerbation of chronic obstructive pulmonary disease and its association with patient outcomes. Hosp Pract (1995) 44: 207–212.

Google Scholar, Crossref, Indexed at

17. Vermeeren MA, Schols AM, Wouters EF (1997) Effects of an acute exacerbation on nutritional and metabolic profile of patients with COPD. Eur Respir J 10: 2264-2269.

Google Scholar, Crossref, Indexed at